<DOC>
	<DOCNO>NCT00779064</DOCNO>
	<brief_summary>This clinical study investigate pharmacokinetics , pharmacodynamic effect safety BAY 59-7939 patient atrial fibrillation ( originally describe Japanese ) .</brief_summary>
	<brief_title>BAY59-7939 , Japanese Phase II Atrial FibrillationTrial Status</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>20 year old Japanese male female Non valvular atrial fibrillation document ECG Patients age 60 year old risk stroke Prior stroke TIA Patients anticoagulant contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>